Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Cash & Current Investments: 2009-2024

Historic Cash & Current Investments for Iovance Biotherapeutics (IOVA) over the last 11 years, with Dec 2024 value amounting to $323.8 million.

  • Iovance Biotherapeutics' Cash & Current Investments rose 83.23% to $300.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 24.94%. This contributed to the annual value of $323.8 million for FY2024, which is 15.69% up from last year.
  • Per Iovance Biotherapeutics' latest filing, its Cash & Current Investments stood at $323.8 million for FY2024, which was up 15.69% from $279.9 million recorded in FY2023.
  • Iovance Biotherapeutics' 5-year Cash & Current Investments high stood at $323.8 million for FY2024, and its period low was $279.9 million during FY2023.
  • For the 2-year period, Iovance Biotherapeutics' Cash & Current Investments averaged around $301.8 million, with its median value being $301.8 million (2023).
  • Data for Iovance Biotherapeutics' Cash & Current Investments shows a peak YoY grew of 15.69% (in 2024) over the last 5 years.
  • Iovance Biotherapeutics' Cash & Current Investments (Yearly) stood at $279.9 million in 2023, then climbed by 15.69% to $323.8 million in 2024.